Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Grafalon® is Neovii main product

Neovii was founded in 1979 following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals.

Lunan Pharmaceutical Group is an integrated pharmaceutical group setting production, scientific research and sale of traditional Chinese medicines, chemicals, biological products in one, a national innovative enterprise, China Torch Program key high-tech enterprise. 

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. We are a well-known supplier of oncology drugs, surgical drugs, and interventional imaging solutions in China.

Hengrui Pharma ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. We has been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from 47th in 2019 to 32nd in 2022.

Saygen is a part of THESAY Investment group led by Visionary in chair Dr. Noushad Abdulrahiman.

Established in 2013, THESAY is a prominent name among the healthcare distributors in the business supplying a comprehensive range of Medical and Pharmaceutical products from more than 50 multinational companies across the globe. We have built our brand and its reputation as a trust-worthy and result-oriented organization.

With an ever-expanding portfolio of more than 100 specialized products, theSAY Pharma has a significant share of the Healthcare market, encompassing both the Government and Private sectors.